PDF herunterladen
CC BY-NC-ND 4.0 · Indian J Med Paediatr Oncol 2016; 37(03): 131-140
DOI: 10.4103/0971-5851.190358
REVIEW ARTICLE

PET/CT in paediatric malignancies - An update

Subramanyam Padma
Department of Nuclear Medicine and PET/CT, Amrita Institute of Medical Sciences, Cochin, Kerala, India
,
Palaniswamy Shanmuga Sundaram
Department of Nuclear Medicine and PET/CT, Amrita Institute of Medical Sciences, Cochin, Kerala, India
,
Anshu Tewari
Department of Nuclear Medicine and PET/CT, Amrita Institute of Medical Sciences, Cochin, Kerala, India
› Institutsangaben Financial support and sponsorship Nil.
› Weitere Informationen
Auch verfügbar auf
  als PDF herunterladen Lizenzen und Reprints

Abstract

18F-fluorodeoxyglucose positron emission tomography (FDG-PET) is a well-established imaging modality in adult oncological practice. Its role in childhood malignancies needs to be discussed as paediatric malignancies differ from adults in tumor subtypes and they have different tumor biology and FDG uptake patterns. This is also compounded by smaller body mass, dosimetric restrictions, and physiological factors that can affect the FDG uptake. It calls for careful planning of the PET study, preparing the child, the parents, and expertise of nuclear physicians in reporting pediatric positron emission tomography/computed tomography (PET/CT) studies. In a broad perspective, FDG-PET/CT has been used in staging, assessment of therapy response, identifying metastases and as a follow-up tool in a wide variety of pediatric malignancies. This review outlines the role of PET/CT in childhood malignancies other than hematological malignancies such as lymphoma and leukemia.

Keywords

Central nervous system tumors - childhood malignancies - neuroblastoma - positron emission tomography/computed tomography - sarcoma


Publikationsverlauf

Artikel online veröffentlicht:
12. Juli 2021

© 2016. Indian Society of Medical and Paediatric Oncology. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/.)

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India

 

  • References

  • 1 Hamblen SM, Lowe VJ. Clinical 18F-FDG oncology patient preparation techniques. J Nucl Med Technol 2003;31:3-10.
  • 2 Gordon I. Issues surrounding preparation, information and handling the child and parent in nuclear medicine. J Nucl Med 1998;39:490-4.
  • 3 Jeffrey BG, Peter LB, Richard TC, Charles JC, Fred GD, Burton SE, et al. American Society of Anesthesiologists, task force on sedation and analgesia by non-anesthesiologists: Practice guidelines for sedation and analgesia by non-anesthesiologists. Anesthesiology 2002;96:1004-17.
  • 4 American Academy of Pediatrics Committee on Drugs: Guidelines for monitoring and management of pediatric patients during and after sedation for diagnostic and therapeutic procedures. Pediatrics 1992;89 (6 Pt 1):1110-5.
  • 5 Visvikis D, Costa DC, Croasdale I, Lonn AH, Bomanji J, Gacinovic S, et al. CT-based attenuation correction in the calculation of semi-quantitative indices of [18F] FDG uptake in PET. Eur J Nucl Med Mol Imaging 2003;30:344-53.
  • 6 Yeung HW, Sanches A, Squire OD, Macapinlac HA, Larson SM, Erdi YE. Standardized uptake value in pediatric patients: An investigation to determine the optimum measurement parameter. Eur J Nucl Med Mol Imaging 2002;29:61-6.
  • 7 Schelbert HR, Hoh CK, Royal HD, Brown M, Dahlbom MN, Dehdashti F, et al. Procedure guideline for tumor imaging using fluorine-18-FDG. Society of Nuclear Medicine. J Nucl Med 1998;39:1302-5.
  • 8 Delbeke D, Coleman RE, Guiberteau MJ, Brown ML, Royal HD, Siegel BA, et al. Procedure guideline for tumor imaging with 18F-FDG PET/CT 1.0. J Nucl Med 2006;47:885-95.
  • 9 Ruotsalainen U, Suhonen-Polvi H, Eronen E, Kinnala A, Bergman J, Haaparanta M, et al. Estimated radiation dose to the newborn in FDG-PET studies. J Nucl Med 1996;37:387-93.
  • 10 Schöder H, Gönen M. Screening for cancer with PET and PET/CT: Potential and limitations. J Nucl Med 2007;48 Suppl 1:4S-18S.
  • 11 Bertell R, Ehrle LH, Schmitz-Feuerhake I. Pediatric CT research elevates public health concerns: Low-dose radiation issues are highly politicized. Int J Health Serv 2007;37:419-39.
  • 12 Grant FD. Normal variations and benign findings in pediatric 18F-FDG-PET/CT. PET Clin 2014;9:195-208.
  • 13 Gurney JG, Young JL, Jr, Roffers SD, Smith MA, Bunin GR. Soft tissue sarcomas. In: Ries LAG, Smith MA, Gurney JG, et al.., editors. Cancer incidence and survival among children and adolescents: United States SEER Program 1975–1995. National Cancer Institute; 1999. pp. 111-1223.
  • 14 Link MP, Gebhardt M, Meyers P. Osteosarcoma. In: Pizzo P, Poplack D, editors. Principles and Practice of Pediatric Oncology. 5th ed. Philadelphia: Lippincott Williams and Wilkins; 2006. p. 1074-115.
  • 15 Charest M, Hickeson M, Lisbona R, Novales-Diaz JA, Derbekyan V, Turcotte RE. FDG PET/CT imaging in primary osseous and soft tissue sarcomas: A retrospective review of 212 cases. Eur J Nucl Med Mol Imaging 2009;36:1944-51.
  • 16 Mody RJ, Bui C, Hutchinson RJ, Yanik GA, Castle VP, Frey KA, et al. FDG PET imaging of childhood sarcomas. Pediatr Blood Cancer 2010;54:222-7.
  • 17 Doorn PF, Molenaar WM, Buter J, Hoekstra HJ. Malignant peripheral nerve sheath tumors in patients with and without neurofibromatosis. Eur J Surg Oncol 1995;21:78-82.
  • 18 Jerusalem G, Beguin Y, Fassotte MF, Najjar F, Paulus P, Rigo P, et al. Whole-body positron emission tomography using 18F-fluorodeoxyglucose for posttreatment evaluation in Hodgkin's disease and non-Hodgkin's lymphoma has higher diagnostic and prognostic value than classical computed tomography scan imaging. Blood 1999;94:429-33.
  • 19 Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000;92:205-16.
  • 20 Franzius C, Sciuk J, Brinkschmidt C, Jürgens H, Schober O. Evaluation of chemotherapy response in primary bone tumors with F-18 FDG positron emission tomography compared with histologically assessed tumor necrosis. Clin Nucl Med 2000;25:874-81.
  • 21 Cohen MD. Imaging of children with cancer. St. Louis: Mosby Yearbook; 1992. p. 89-134.
  • 22 Shulkin BL, Hutchinson RJ, Castle VP, Yanik GA, Shapiro B, Sisson JC. Neuroblastoma: Positron emission tomography with 2-[fluorine-18]-fluoro-2-deoxy-D-glucose compared with metaiodobenzylguanidine scintigraphy. Radiology 1996;199:743-50.
  • 23 Franzius C, Hermann K, Weckesser M, Kopka K, Juergens KU, Vormoor J, et al. Whole-body PET/CT with 11C-meta-hydroxyephedrine in tumors of the sympathetic nervous system: Feasibility study and comparison with 123I-MIBG SPECT/CT. J Nucl Med 2006;47:1635-42.
  • 24 Vaidyanathan G, Affleck DJ, Zalutsky MR. Validation of 4-[fluorine-18]fluoro-3-iodobenzylguanidine as a positron-emitting analog of MIBG. J Nucl Med 1995;36:644-50.
  • 25 Packer RJ. Brain tumors in children. Arch Neurol 1999;56:421-5.
  • 26 Levivier M, Becerra A, De Witte O, Brotchi J, Goldman S. Radiation necrosis or recurrence. J Neurosurg 1996;84:148-9.
  • 27 Olivero WC, Dulebohn SC, Lister JR. The use of PET in evaluating patients with primary brain tumours: Is it useful? J Neurol Neurosurg Psychiatry 1995;58:250-2.
  • 28 Ricci PE, Karis JP, Heiserman JE, Fram EK, Bice AN, Drayer BP. Differentiating recurrent tumor from radiation necrosis: Time for re-evaluation of positron emission tomography? AJNR Am J Neuroradiol 1998;19:407-13.
  • 29 Jadvar H, Connolly LP, Fahey FH, Shulkin BL. PET and PET/CT in pediatric oncology. Semin Nucl Med 2007;37:316-31.
  • 30 Chen W. Clinical applications of PET in brain tumors. J Nucl Med 2007;48:1468-81.
  • 31 Ishiwata K, Kubota K, Murakami M, Kubota R, Sasaki T, Ishii S, et al. Re-evaluation of amino acid PET studies: Can the protein synthesis rates in brain and tumor tissues be measured in vivo ? J Nucl Med 1993;34:1936-43.
  • 32 Jager PL, Vaalburg W, Pruim J, de Vries EG, Langen KJ, Piers DA. Radiolabeled amino acids: Basic aspects and clinical applications in oncology. J Nucl Med 2001;42:432-45.
  • 33 Spaeth N, Wyss MT, Weber B, Scheidegger S, Lutz A, Verwey J, et al. Uptake of 18F-fluorocholine, 18F-fluoroethyl-L-tyrosine, and 18F-FDG in acute cerebral radiation injury in the rat: Implications for separation of radiation necrosis from tumor recurrence. J Nucl Med 2004;45:1931-8.
  • 34 Chen W, Silverman DH. Advances in evaluation of primary brain tumors. Semin Nucl Med 2008;38:240-50.
  • 35 Padma MV, Said S, Jacobs M, Hwang DR, Dunigan K, Satter M, et al. Prediction of pathology and survival by FDG PET in gliomas. J Neurooncol 2003;64:227-37.
  • 36 Wong TZ, Turkington TG, Hawk TC, Coleman RE. PET and brain tumor image fusion. Cancer J 2004;10:234-42.
  • 37 Rasey IS, Grierson JR, Wierns LW, Schwartz JL, Jordan R, Vesselle H. Validation of FLT uptake as a measure of thymidine kinase-1 activity in A549 carcinoma cells. J Nucl Med 2002;43:1210-7.
  • 38 Chen W, Cloughesy T, Kamdar N, Satyamurthy N, Bergsneider M, Liau L, et al. Imaging proliferation in brain tumors with 18F-FLT PET: Comparison with 18F-FDG. J Nucl Med 2005;46:945-52.
  • 39 International Germ Cell Consensus Classification: A prognostic factor-based staging system for metastatic germ cell cancers. International Germ Cell Cancer Collaborative Group. J Clin Oncol 1997;15:594-603.
  • 40 George JB, Robert JM. Testicular Germ-Cell Cancer. N Engl J Med 1997;337:242-54. DOI: 10.1056/NEJM199707243370406.
  • 41 Litten JB, Tomlinson GE. Liver tumors in children. Oncologist 2008;13:812-20.
  • 42 Malogolowkin MH, Katzenstein HM, Meyers RL, Krailo MD, Rowland JM, Haas J, et al. Redefining the role of doxorubicin for the treatment of children with hepatoblastoma. J Clin Oncol 2008;26:2379-83.
  • 43 Meyers RL. Tumors of the liver in children. Surg Oncol 2007;16:195-203.
  • 44 Herzog CE, Behrman RE, Jenson HB, Stanton B. Neoplasms of the liver. In: Kliegman R, editor. Nelson Textbook of Pediatrics. Philadelphia: Saunders Elsevier; 2007.
  • 45 Philip I, Shun A, McCowage G, Howman-Giles R. Positron emission tomography in recurrent hepatoblastoma. Pediatr Surg Int 2005;21:341-5.
  • 46 Sironi S, Messa C, Cistaro A, Landoni C, Provenzi M, Giraldi E, et al. Recurrent hepatoblastoma in orthotopic transplanted liver: Detection with FDG positron emission tomography. AJR Am J Roentgenol 2004;182:1214-6.
  • 47 Kinkel K, Lu Y, Both M, Warren RS, Thoeni RF. Detection of hepatic metastases from cancers of the gastrointestinal tract by using noninvasive imaging methods (US, CT, MR imaging, PET): A meta-analysis. Radiology 2002;224:748-56.
  • 48 Fuchs J, Szavay P, Luithle T, Furtwängler R, Graf N. Surgical implications for liver metastases in nephroblastoma – Data from the SIOP/GPOH study. Surg Oncol 2008;17:33-40.
  • 49 Kong G, Jackson C, Koh DM, Lewington V, Sharma B, Brown G, et al. The use of 18F-FDG PET/CT in colorectal liver metastases – Comparison with CT and liver MRI. Eur J Nucl Med Mol Imaging 2008;35:1323-9.
  • 50 Shulkin BL, Chang E, Strouse PJ, Bloom DA, Hutchinson RJ. PET FDG studies of Wilms tumors. J Pediatr Hematol Oncol 1997;19:334-8.
  • 51 Klöppel G, Anlauf M. Gastrinoma – Morphological aspects. Wien Klin Wochenschr 2007;119:579-84.
  • 52 Pellicano R, De Angelis C, Resegotti A, Rizzetto M. Zollinger-Ellison syndrome in 2006: Concepts from a clinical point of view. Panminerva Med 2006;48:33-40.
  • 53 Lindström P. Aromatic-L-amino-acid decarboxylase activity in mouse pancreatic islets. Biochim Biophys Acta 1986;884:276-81.
  • 54 Mohnike K, Blankenstein O, Christesen HT, De Lonlay J, Hussain K, Koopmans KP, et al. Proposal for a standardized protocol for 18F-DOPA-PET (PET/CT) in congenital hyperinsulinism. Horm Res 2006;66:40-2.
  • 55 Hardy OT, Hernandez-Pampaloni M, Saffer JR, Scheuermann JS, Ernst LM, Freifelder R, et al. Accuracy of [18F] fluorodopa positron emission tomography for diagnosing and localizing focal congenital hyperinsulinism. J Clin Endocrinol Metab 2007;92:4706-11.
  • 56 Franzius C, Sciuk J, Daldrup-Link HE, Jürgens H, Schober O. FDG-PET for detection of osseous metastases from malignant primary bone tumours: Comparison with bone scintigraphy. Eur J Nucl Med 2000;27:1305-11.
  • 57 Kneisl JS, Patt JC, Johnson JC, Zuger JH. Is PET useful in detecting occult nonpulmonary metastases in pediatric bone sarcomas? Clin Orthop Relat Res 2006;450:101-4.
  • 58 Allan R, Biassoni L. Guidelines for the use of PET- CT in children. 2nd ed. Available from: .